POLYGON Therapeutics announces a collaboration with GTP Bioways for the development of its flagship molecule, PLG-101
Paris, Toulouse – February 28th, 2023. POLYGON, a Paris-based preclinical-stage biotech company, is announcing a collaboration with GTP Bioways for the cell line development of its innovative biotherapeutics aiming to improve the outcome of cardiovascular diseases and acute immune disorders. The goal of the partnership is to develop robust and scalable cell lines for the production of biopharmaceuticals. With a highly committed and experienced team of scientists and researchers, POLYGON is dedicated to delivering innovative and effective therapies, to the 500+ million people affected by cardiovascular conditions worldwide, with a focus on acute events. Its goal is to provide new hope to patients and families affected by these diseases and to have a positive impact on the global healthcare landscape.
The company’s lead product, PLG-101, is a cutting-edge therapy to treat acute immune-related cardiovascular disease. This specific monoclonal antibody targets CD8+ T cells, a type of immune cell that plays a key role in the development of cardiac damages after myocardial infarction. By targeting CD8+ T cells, PLG-101 has the potential to prevent the damaging effects of the specific immune reaction.
